Over the past few months, organizations and individuals in the ME/CFS community have kept the drumbeat going on email and letter writing campaigns urging the FDA to schedule an ME/CFS stakeholder meeting (a dialog to accelerate risk-benefit assessment of drugs for treating ME/CFS patients, a population currently with “unmet medical need"). And today, it happened, according to Cort Johnson’s post on Phoenix Rising (PhoenixRising.me):
Success! FDA Commits to Stakeholder Meeting…
Your Voices Made the Difference
We are very happy to announce that during a conference call, Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research at the FDA, made a commitment to the ME/CFS community to hold a Stakeholder Meeting.
We’ll let you know more as the meeting and agenda for the meeting develops. In the meantime pat yourself on the back and thanks for your support! Working together we can make a difference for ME/CFS.